Literature DB >> 21628573

Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis.

Richard Marcotte1, Harvey W Smith, Virginie Sanguin-Gendreau, Rosalie V McDonough, William J Muller.   

Abstract

The tyrosine kinase c-Src is activated in a large proportion of breast cancers, in which it is thought to play a key role in promoting the malignant phenotype. c-Src activity is also elevated in transgenic mouse models of breast cancer, including the widely used polyomavirus middle-T antigen (PyVmT) model, which provides an opportunity to study the importance of c-Src in mammary tumorigenesis. However, germline c-Src deletion in mammary epithelial and stromal compartments complicates the interpretation of in vivo tumorigenesis studies as a result of severe defects in mammary gland development. We have therefore engineered a mouse strain in which deletion of c-Src can be targeted to the mammary epithelium. We demonstrate that mammary epithelial disruption of c-Src impairs proliferation and tumor progression driven by PyVmT in vivo. Whereas related kinases substitute for c-Src in PyVmT signaling, c-Src ablation impairs cell cycle progression with decreased cyclin expression and elevated expression of cyclin-dependent kinase inhibitors. Our data indicate that c-Src has essential and unique functions in proliferation and tumor progression in this mouse model that may also be important in certain contexts in some human breast cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628573      PMCID: PMC3286961          DOI: 10.1073/pnas.1018861108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling.

Authors:  Egle Avizienyte; Anne W Wyke; Robert J Jones; Gordon W McLean; M Andrew Westhoff; Valerie G Brunton; Margaret C Frame
Journal:  Nat Cell Biol       Date:  2002-08       Impact factor: 28.824

2.  Transgenic Polyoma middle-T mice model premalignant mammary disease.

Authors:  J E Maglione; D Moghanaki; L J Young; C K Manner; L G Ellies; S O Joseph; B Nicholson; R D Cardiff; C L MacLeod
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

Review 3.  Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.

Authors:  Erica L Mayer; Ian E Krop
Journal:  Clin Cancer Res       Date:  2010-07-15       Impact factor: 12.531

4.  Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction.

Authors:  Donald E White; Natasza A Kurpios; Dongmei Zuo; John A Hassell; Sandra Blaess; Ulrich Mueller; William J Muller
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

5.  Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product.

Authors:  A E Ottenhoff-Kalff; G Rijksen; E A van Beurden; A Hennipman; A A Michels; G E Staal
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

Review 6.  Src kinases as therapeutic targets for cancer.

Authors:  Lori C Kim; Lanxi Song; Eric B Haura
Journal:  Nat Rev Clin Oncol       Date:  2009-10       Impact factor: 66.675

7.  c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential.

Authors:  Richard Marcotte; Lixin Zhou; Harold Kim; Calvin D Roskelly; William J Muller
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

8.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.

Authors:  C T Guy; R D Cardiff; W J Muller
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

9.  Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis.

Authors:  E R Andrechek; W R Hardy; P M Siegel; M A Rudnicki; R D Cardiff; W J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

10.  Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.

Authors:  E Y Lin; A V Nguyen; R G Russell; J W Pollard
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

View more
  27 in total

1.  Progress in breast cancer research.

Authors:  Kornelia Polyak; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-13       Impact factor: 11.205

Review 2.  Connexin43 cardiac gap junction remodeling: lessons from genetically engineered murine models.

Authors:  Benjamin F Remo; Steven Giovannone; Glenn I Fishman
Journal:  J Membr Biol       Date:  2012-06-22       Impact factor: 1.843

3.  Oncolytic virotherapy for ovarian cancer.

Authors:  Shoudong Li; Jessica Tong; Masmudur M Rahman; Trevor G Shepherd; Grant McFadden
Journal:  Oncolytic Virother       Date:  2012-08

4.  Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.

Authors:  Juan Li; Dominique Davidson; Cleiton Martins Souza; Ming-Chao Zhong; Ning Wu; Morag Park; William J Muller; André Veillette
Journal:  Mol Cell Biol       Date:  2015-09-21       Impact factor: 4.272

5.  Rheb1-Independent Activation of mTORC1 in Mammary Tumors Occurs through Activating Mutations in mTOR.

Authors:  Bin Xiao; Dongmei Zuo; Alison Hirukawa; Robert D Cardiff; Richard Lamb; Nahum Sonenberg; William J Muller
Journal:  Cell Rep       Date:  2020-04-28       Impact factor: 9.423

6.  Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice.

Authors:  Linxiang Lan; Jane D Holland; Jingjing Qi; Stefanie Grosskopf; Jörg Rademann; Regina Vogel; Balázs Györffy; Annika Wulf-Goldenberg; Walter Birchmeier
Journal:  EMBO J       Date:  2015-03-03       Impact factor: 11.598

7.  SRC Increases MYC mRNA Expression in Estrogen Receptor-Positive Breast Cancer via mRNA Stabilization and Inhibition of p53 Function.

Authors:  Christopher Abdullah; Hasan Korkaya; Shinji Iizuka; Sara A Courtneidge
Journal:  Mol Cell Biol       Date:  2018-02-27       Impact factor: 4.272

8.  Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.

Authors:  Shalini Jain; Xiao Wang; Chia-Chi Chang; Catherine Ibarra-Drendall; Hai Wang; Qingling Zhang; Samuel W Brady; Ping Li; Hong Zhao; Jessica Dobbs; Matt Kyrish; Tomasz S Tkaczyk; Adrian Ambrose; Christopher Sistrunk; Banu K Arun; Rebecca Richards-Kortum; Wei Jia; Victoria L Seewaldt; Dihua Yu
Journal:  Cancer Res       Date:  2015-09-17       Impact factor: 12.701

9.  C-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics.

Authors:  Xiang Xiao; Dolores D Mruk; Faith L Cheng; C Yan Cheng
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

10.  YES oncogenic activity is specified by its SH4 domain and regulates RAS/MAPK signaling in colon carcinoma cells.

Authors:  Fanny Dubois; Cédric Leroy; Valérie Simon; Christine Benistant; Serge Roche
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.